Evidence map›Paper›PMID 33763874›Full record

Trial reportThe British journal of dermatology2021

Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.

A S Van Voorhees, L Stein Gold, M Lebwohl, B Strober, H Sofen, K Papp, J Bagel, Z Zhang, M Paris, Y Wang

Abstract readClinical Trial, Phase IIILetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A S Van VoorheesEastern Virginia Medical School, Norfolk, VA, USA.ORCID 0000-0003-3863-3842
L Stein GoldHenry Ford Health System, West Bloomfield, MI, USA.
M LebwohlIcahn School of Medicine at Mount Sinai, New York, NY, USA.
B StroberYale University, New Haven, CT, USA.ORCID 0000-0002-8394-2057
H SofenUCLA School of Medicine, Los Angeles, CA, USA.ORCID 0000-0001-7789-6915
K PappProbity Medical Research, Waterloo, ON, Canada.ORCID 0000-0001-9557-3642
J BagelPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA.
Z ZhangAmgen Inc., Thousand Oaks, CA, USA.
M ParisAmgen Inc., Thousand Oaks, CA, USA.
Y WangAmgen Inc., Thousand Oaks, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PsoriasisScalpThalidomideAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodHumansSeverity of Illness IndexTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalapremilastThalidomide

Identifiers

PMID33763874
PMCPMC8518877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.